

**AstraZeneca Independent Medical Education Grants Report
Frequently Asked Questions**

1. Why is AstraZeneca publicly disclosing independent medical education grants?

As part of our effort to be more transparent regarding our initiatives to impact patient health both inside and outside the lab, AstraZeneca decided to post information about our medical education grants on our US web site, including the names of medical education grant recipients, the purpose of the grant and the grant amount.

AstraZeneca has a strong heritage of discovering and delivering medicines designed to improve the health of patients around the world managing a variety of medical conditions. While drug discovery and delivery is what we do, we also know that *how* we do business is important to the many people whose lives we touch, including patients, physicians, employees, investors and the communities around us. Maintaining the trust of those groups is very important to us.

2. What is the position of AstraZeneca on transparency and its importance to the healthcare industry?

AstraZeneca believes it is important to be open about how we conduct our business and what we are doing to make a meaningful difference to patient health. We believe in providing information to the public about our company, our products and how we do business as part of our commitment to corporate responsibility and to improving patient health.

3. What information will be on the report?

Grant funding reported here represents grant requestor(s), the purpose of the grant and the grant amount provided during a specified time period. The data posted in this report is based on information provided to us by the grant requestor specific to independent medical education grants awarded to organizations, associations, academic institutions, hospitals and medical education companies in 2009.

4. Why are there two organizations listed as “requestor” in some cases on your report?

The data posted includes the grant requestor. In some instances, more than one entity will be responsible for providing the educational activity and we have included that information.

5. Are organizations receiving AstraZeneca support aware of the transparency initiative?

In March 2008, AstraZeneca announced its plans for enhanced transparency around key areas of the business, including medical education grants. In addition, all independent medical education grants awarded from 2008-2009 have a signed letter of agreement between AstraZeneca and the educational providers that includes a section that makes clear that AstraZeneca will disclose information related to the grant.

6. What types of independent education programs does AstraZeneca support?

The independent medical education programs that we support include educational activities certified for CME/CE for physicians, pharmacists, nurses and other health care professionals, as well as activities without continuing education credit such as for scientists and fellows. We accept applications from a wide range of health care organizations, associations, academic institutions, hospitals and medical education companies.

7. How does AstraZeneca make grant funding decisions?

When evaluating grant applications for education programs, AstraZeneca looks for programs that:

- Meet an educational need by providing information designed to assist health care professionals in their efforts to enhance patient care
- Further the understanding of emerging therapies based on a documented unmet need
- Incorporate evidence-based medicine in the program objectives and methodology
- Assist health care professionals in carrying out diagnosis and treatment strategies more effectively and efficiently
- Support the efforts of health care professionals to broaden patient knowledge and awareness of disease states and treatment options.

All grant applications received from educational providers are reviewed using objective criteria based on AstraZeneca policy and guidance by the Medical Education Grants Office (MEGO). AstraZeneca policies on independent medical education grant decision-making are consistent with FDA Guidance, the PhRMA Code, OIG Compliance Program Guidance for Pharmaceutical Manufacturers, and the Accreditation Council for Continuing Medical Education Standards for Commercial Support.

While we do support some general health initiatives, we primarily support educational activities aligned with our areas of interest and expertise for example, in the therapeutic areas of cardiovascular disease, gastrointestinal disorders, respiratory, oncology and psychiatry.

8. How can organizations apply for medical education grant funding?

Organizations can visit our Website at www.astrazenecagrants.com to fill out an application for consideration for grant funding. Priority is given to requests that focus on diseases or conditions relevant to the therapeutic areas where AstraZeneca has expertise and can make a meaningful difference to the health of patients.

9. Does previous support of a program by AstraZeneca guarantee future support?

No. Each medical education grant request is evaluated on its own merits.

10. How does AstraZeneca ensure that grants do not pose a conflict of interest with recipient organizations?

AstraZeneca believes transparency and ethical behavior are critical components to advancing patient health, which is why our employees are trained on our Code of Conduct and our Independent Education Grants policy, which prohibits the exertion of control or influence over any aspect of independent medical education activities.

11. For grants supported by AstraZeneca in partnership with another commercial supporter, will AstraZeneca disclose the portions of grant payments provided by the partner pharmaceutical company?

No. AstraZeneca will only report its portion of grant payments made in collaboration with other pharmaceutical companies.